<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Pro | wechat-feeds</title><link>https://wechat.privacyhide.com/</link><description>聚焦生物医药前沿，洞察研发投资风向</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 24 Jan 2021 00:06:40 +0800</pubDate><image><url>http://wx.qlogo.cn/mmhead/Q3auHgzwzM5PsTq2KuxPSBicXVWtAO0eaX51UAzakRZ92kT72RDwYIg/64</url><title>医药魔方Pro | wechat-feeds</title><link>https://wechat.privacyhide.com/</link><width>64</width><height>64</height></image><item><title>CAR-T新开关——来那度胺 | Science子刊最新成果</title><link>https://mp.weixin.qq.com/s/5hGOXh2NBc0TA5cc_wO8nQ</link><description></description><content:encoded><![CDATA[CAR-T新开关——来那度胺 | Science子刊最新成果]]></content:encoded><pubDate>Sat, 23 Jan 2021 21:03:36 +0800</pubDate></item><item><title>saRNA疗法成香饽饽！勃林格殷格翰、阿斯利康后，Servier也携超2亿美元入场</title><link>https://mp.weixin.qq.com/s/PKlRkb6aCpo8UL5Lz_AtFg</link><description></description><content:encoded><![CDATA[saRNA疗法成香饽饽！勃林格殷格翰、阿斯利康后，Servier也携超2亿美元入场]]></content:encoded><pubDate>Fri, 22 Jan 2021 21:00:42 +0800</pubDate></item><item><title>下一代罕见病基因疗法，砥砺前行</title><link>https://mp.weixin.qq.com/s/gmcD69_hIlFavUuvCpu6gw</link><description></description><content:encoded><![CDATA[下一代罕见病基因疗法，砥砺前行]]></content:encoded><pubDate>Thu, 21 Jan 2021 19:08:18 +0800</pubDate></item><item><title>收购浪潮冲击下，ADC癌症治疗火热</title><link>https://mp.weixin.qq.com/s/8okugltD-ZgZdA_u4P9TyA</link><description></description><content:encoded><![CDATA[收购浪潮冲击下，ADC癌症治疗火热]]></content:encoded><pubDate>Wed, 20 Jan 2021 19:49:14 +0800</pubDate></item><item><title>不是CAR-T/NK/M，新型细胞治疗技术来了，目标是攻克实体瘤！</title><link>https://mp.weixin.qq.com/s/mek9J9u3z_dkq3xs20nJbA</link><description></description><content:encoded><![CDATA[不是CAR-T/NK/M，新型细胞治疗技术来了，目标是攻克实体瘤！]]></content:encoded><pubDate>Tue, 19 Jan 2021 13:26:44 +0800</pubDate></item><item><title>小分子RNA靶向疗法热潮渐起，全球制药巨头纷涌而至</title><link>https://mp.weixin.qq.com/s/nuRhH5lBZR892z98wpT3oQ</link><description></description><content:encoded><![CDATA[小分子RNA靶向疗法热潮渐起，全球制药巨头纷涌而至]]></content:encoded><pubDate>Mon, 18 Jan 2021 21:03:45 +0800</pubDate></item><item><title>赛诺菲押注KLRG1抗体！这家免疫疗法公司完成4200万美元A1轮融资，主攻癌症和自身免疫性疾病</title><link>https://mp.weixin.qq.com/s/TMhgFxtbL_L0IQe3eiSdUg</link><description></description><content:encoded><![CDATA[赛诺菲押注KLRG1抗体！这家免疫疗法公司完成4200万美元A1轮融资，主攻癌症和自身免疫性疾病]]></content:encoded><pubDate>Sun, 17 Jan 2021 20:59:08 +0800</pubDate></item><item><title>CRISPR治疗痤疮！卢冠达联合创办的Eligo与GSK达成最新合作，交易总额2.24亿美元</title><link>https://mp.weixin.qq.com/s/cgRmLJIdLmPM-e2jzSQebw</link><description></description><content:encoded><![CDATA[CRISPR治疗痤疮！卢冠达联合创办的Eligo与GSK达成最新合作，交易总额2.24亿美元]]></content:encoded><pubDate>Sat, 16 Jan 2021 21:01:13 +0800</pubDate></item><item><title>赛诺菲斥资超10亿美元，拿下ILT2抗体！这款新型癌症免疫疗法究竟有何优势？</title><link>https://mp.weixin.qq.com/s/A7ksYw-dJIzoWeutQy1q8A</link><description></description><content:encoded><![CDATA[赛诺菲斥资超10亿美元，拿下ILT2抗体！这款新型癌症免疫疗法究竟有何优势？]]></content:encoded><pubDate>Fri, 15 Jan 2021 21:11:37 +0800</pubDate></item><item><title>主攻RNAi疗法！诺奖得主创立的Atalanta以1.1亿美元启动，与Biogen、罗氏已达成合作</title><link>https://mp.weixin.qq.com/s/GN96L8Tos0cIRhjWTJBE9A</link><description></description><content:encoded><![CDATA[主攻RNAi疗法！诺奖得主创立的Atalanta以1.1亿美元启动，与Biogen、罗氏已达成合作]]></content:encoded><pubDate>Thu, 14 Jan 2021 21:00:10 +0800</pubDate></item></channel></rss>